PO.MCB08.01 · 分子与细胞生物学
通过免疫组化(IHC)检测的 MTAP 缺失与通过二代测序(NGS)和 DNA 荧光原位杂交(FISH)检测的 MTAP 纯合缺失的比较
Comparison of MTAP loss by immunohistochemistry (IHC) and MTAP homozygous deletion by next-generation sequencing (NGS) and DNA fluorescence in-situ hybridization (FISH)
该海报暂无可下载的资料
AACR 官方页面
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景:由基因组改变引起的甲硫腺苷磷酸化酶(MTAP)缺失见于约 10%–15% 的实体瘤,包括 NSCLC、PDAC 及其他肿瘤。第二代 MTA 协同型 PRMT5 抑制剂在晚期实体瘤患者中显示出令人鼓舞的疗效和安全性,凸显了精准患者筛选策略的必要性。DNA NGS、DNA FISH 和 IHC 是检测患者肿瘤样本中 MTAP 缺失的主要方法。FISH 因其高空间分辨率和直接的 DNA 水平检测,常被视为确认基因缺失的金标准;然而,其可扩展性有限、周转时间较长且操作复杂,使其在常规筛查中不太实用。NGS 可实现对包括 MTAP 缺失在内的基因组改变进行多重、高通量的检测,具有强大的分析性能和广泛的分子背景信息。它支持从单一肿瘤标本进行治疗选择、预后评估和试验入组资格判定。IHC 具有周转快、保留肿瘤形态并可对肿瘤内异质性进行可视化的优势。鉴于 MTA 协同型 PRMT5 抑制剂迄今已展现出的良好结果,随着这些药物开发的推进,检测方法的灵活性对于满足患者和医生多样化的需求十分重要。在此,我们呈现一项评估 IHC、NGS 和 FISH 检测一致性的研究结果,以评估 MTAP 缺失的存在。
方法:我们通过筛选、优化并对 13 种市售抗体克隆进行生物物理表征,开发了一种 MTAP IHC 检测方法。随后,我们在 >160 例实体瘤样本上使用经过验证的 DNA NGS 和/或 FISH 对我们的 IHC 检测进行了基准评估。
结果:IHC 与 NGS 高度一致(>90% 一致性,Cohen's Kappa >0.85),与 FISH 也高度一致(>85% 一致性,Cohen's Kappa >0.70)。类似地,NGS 与 FISH 显示出强一致性(>90% 一致性,Cohen's Kappa >0.80)。通过对肿瘤形态的深入评估和对 FISH 图像的复核,我们将大多数不一致情况(即 IHC 上表现出明显 MTAP 缺失但 NGS 和/或 FISH 未检测到伴随的 MTAP 缺失)归因于低/临界的肿瘤纯度。当研究我们队列中通过 NGS 和 FISH 检测的外显子水平 MTAP 纯合缺失的初步模式时,我们观察到在部分性 MTAP 缺失的肿瘤中,方法间存在一定的异质性。
结论:这些数据表明 IHC、NGS 和 FISH 在检测 MTAP 缺失方面总体一致性高。IHC 可提供快速筛查并保留形态学背景,而 NGS 和 FISH 则提供正交的分子分辨率。我们的研究结果支持将 IHC 作为一种实用的 MTAP 缺失检测方法,并与 NGS 或 FISH 联合使用。
查看英文原文 English abstract
Background: Methylthioadenosine phosphorylase (MTAP) deletion, resulting from genomic alteration, is observed in approximately 10%-15% of solid tumors, including NSCLC, PDAC, and others. Second-generation MTA-cooperative PRMT5 inhibitors have shown encouraging efficacy and safety in patients with advanced solid tumors, emphasizing the need for precise patient selection strategies. DNA NGS, DNA FISH, and IHC are the primary methods of MTAP loss detection in patient tumor samples. FISH is often considered the gold standard for confirming gene deletions due to its high spatial resolution and direct DNA-level detection; however, its limited scalability, longer turnaround, and operational complexity make it less practical for routine screening. NGS enables multiplexed, high-throughput detection of genomic alterations including MTAP deletions with strong analytical performance and broad molecular context. It supports treatment selection, prognostic assessment, and trial eligibility from a single tumor specimen. IHC offers rapid turnaround, preserves tumor morphology, and allows visualization of intratumoral heterogeneity. With the promising results that have been shown so far for MTA-cooperative PRMT5 inhibitors, flexibility in testing methods is important to meet the diverse needs of patients and physicians as the development of these agents moves forward. Here, we present the results of a study assessing the concordance of IHC, NGS, and FISH testing to assess the presence of MTAP loss.
Methods: We developed an MTAP IHC assay by screening, optimizing, and biophysically characterizing 13 commercially available antibody clones. We subsequently benchmarked our IHC assay using validated DNA NGS and/or FISH on > 160 solid tumor samples. Results: IHC was highly concordant with NGS (> 90% agreement, Cohen's Kappa > 0.85) and with FISH (> 85% agreement, Cohen's Kappa > 0.70). Similarly, NGS and FISH showed strong concordance (> 90% agreement, Cohen's Kappa > 0.80). Through in-depth assessment of tumor morphology and review of FISH images, we attributed most discordance in the context of apparent MTAP loss on IHC without concomitant MTAP deletion detection on NGS and/or FISH to low/borderline tumor purity. When investigating preliminary patterns of exon-level MTAP homozygous deletion by NGS and FISH in our cohort, we observed some heterogeneity between methods in tumors with partial MTAP deletion.
Conclusions: These data demonstrate high overall agreement among IHC, NGS, and FISH for the detection of MTAP loss. IHC offers rapid screening with retained morphologic context, whereas NGS and FISH provide orthogonal molecular resolution. Our findings support IHC as a practical method for MTAP loss detection, along with NGS or FISH.
利益披露 Disclosure
L. Huang,
Bristol Myers Squibb Employment, Stock.
L. Giampapa,
Bristol Myers Squibb Employment, Stock, ), Travel.
P. Montanaro,
Bristol Myers Squibb Employment.
I. Krishna,
Bristol Myers Squibb Employment, Travel.
Thermo Fisher Employment, Travel.
Stryker Employment, Travel.
Novo Nordisk Stock.
S. Chilewski,
Bristol Myers Squibb Employment, Stock, Travel, Patent, Other, Research funding.
St. Joseph's University Patent.
H. Hwangbo,
Bristol Myers Squibb Employment, Stock, Travel.
W. Chou,
Bristol Myers Squibb Employment, Stock.
S. Jamerson,
Bristol Myers Squibb Employment, Travel.
L. Dong,
Bristol Myers Squibb Employment, Stock, Travel.
O. Adelakun,
Bristol Myers Squibb Employment, Stock, Patent.
J. Coculo,
Bristol Myers Squibb Employment, Stock, Travel, Other, Research funding.
J. Rassa,
Bristol Myers Squibb Employment, Stock, Travel, Other, Research funding.
J. Baden,
Bristol Myers Squibb Employment, Stock.
Johnson and Johnson Stock.
T. Hollmann,
Bristol Myers Squibb Employment, Stock.
I. Katsyv,
Bristol Myers Squibb Stock.
Abbvie Stock.
Ark Genomic Rev ETC Stock.
Ark Innovation ETC Stock.
GE Healthcare Stock.
Pfizer Stock.
Sarepta Therapeutics Stock.